"A little learning is a dangerous thing;
Drink deep or taste not the Pierian spring."
-Alexander Pope, 1709
Clinical data are easy to curate. Genomic knowledge is relatively straightforward to acquire. Artificial intelligence is, well…artificial.
Medical wisdom, on the other hand, is rooted deeply in experience. It comes from the immense learning we receive from success and failure, in lives saved and lives lost.
At PierianDx we share with our customers, our partners and our investors a passion for improving patient lives and advancing the field of medicine. We know that it's the sharing of our collective wisdom that empowers this to happen.
This is our story.
Invigorated by the sequencing of the human genome, breakthroughs in basic science are now delivering blockbuster therapies in cancer and other critical indications. A key player, Washington University in St. Louis, led the Human Genome Project and was among the first to validate and report its experience utilizing next generation sequencing clinically. While a leader at Washington University, PierianDx founder and Executive Chairman Dr. Rakesh Nagarajan was a critical innovator of technology-enabled solutions that allowed for processing and interpreting the near-overwhelming amounts of data created in “omic” analyses. The reputation and critical role of Washington University’s molecular diagnostics lab, as well as Dr. Nagarajan’s ongoing participation in key industry leadership groups such as the College of American Pathologists (CAP), has positioned PierianDx as a key enabler of precision medicine.
Washington University in St. Louis plays a crucial role in the mapping of the first human genome.
Washington University creates CAP/CLIA lab for NGS testing. The Genetics and Molecular Pathology departments collaborate to develop Clinical Genomics Workspace (CGW), groundbreaking software for clinical genomics.
Washington University performs a technology transfer after 50+ labs visit to learn how to operationalize clinical NGS testing. Key team members form PierianDx.
After two releases of CGW that offer multi-tenant and exome sequencing support, PierianDx closes Series A funding (14.2 million).
Today, PierianDx has 40+ customers supported by nearly 70 medical, scientific, and technical experts.
Founder and Executive Chairman
Chief Executive Officer
Chief Commercial Officer
Medical Director, Laboratory Director
Vice President, Product Development
Vice President, Product
Vice President, Product
Vice President, Marketing
Director and Centre Head